OrthoPediatrics reported net revenue of $72.7 million for the three months ended September 30, 2026, up 19% from $61.2 million a year earlier. For the nine months, net revenue rose 16% to $202.5 million, and net cash provided by operating activities was $2.1 million, compared with net cash used of $15.2 million a year earlier.
KIDS · Orthopediatrics Corp · Documents
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Third-quarter revenue rose 19% to a record $72.7 million, and full-year 2026 revenue guidance was raised to $270 to $273 million, representing growth of 14 to 16%. Adjusted EBITDA was a record $6.9 million and free cash flow was positive at $1.6 million, while the company reiterated its approximately $25 million adjusted EBITDA guidance.
OrthoPediatrics Corp. presented an investor deck reporting third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier. The company guides full-year 2026 revenue to $270.0 to $273.0 million, 14% to 16% total growth, and adjusted EBITDA of about $25.0 million.
OrthoPediatrics reported record third-quarter 2026 revenue of $72.7 million, up 19% from $61.2 million a year earlier, and a net loss of $5.9 million. Adjusted EBITDA rose to $6.9 million from $6.2 million, and free cash flow was $1.6 million. The company raised its full-year 2026 revenue guidance to $270.0 million to $273.0 million from $265.0 million to $269.0 million.